TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy
Eva Nievergall(South Australian Health and Medical Research Institute), Deborah L. White(ANZCHOG), Wendy N. Erber(The University of Western Australia), Dale B. Watkins(South Australian Health and Medical Research Institute), Samantha J. Busfield(CSL (Australia)), Angel F. López(Centre for Cancer Biology), Teresa Sadras(South Australian Health and Medical Research Institute), Timothy P. Hughes(South Australia Pathology), John Reynolds(Deakin University), Devendra Hiwase(Australasian Leukaemia and Lymphoma Group), Chung Hoow Kok(South Australian Health and Medical Research Institute), G Vairo(CSL (Australia)), Kathryn A. Fuller(The University of Western Australia), David T Yeung(South Australia Pathology), Mark Biondo(CSL (Australia)), Randall Grose(South Australian Health and Medical Research Institute)
Cited by 50
Related Papers
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
|The Lancet|2005|3.4k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464